Equibles does not estimate personal net worth.
Get an email with a short summary when Karyopharm Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get KPTI alertsThe proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $2,016,134 for Reshma Rangwala in fiscal 2025, including a base salary of $567,736. Disclosed compensation is on record for 3 fiscal years. Reshma Rangwala has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Karyopharm Therapeutics Inc. on May 19, 2026. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Karyopharm Therapeutics Inc. includes Richard Paulson (CEO and Board Member), Senior Clinical (CEO), Michael Mano (General Counsel) and 7 others.
“Really, really excited about ASCO coming up, right? You know, we obviously were selected to break our century results, which is our phase 3 trial evaluating selenixor plus roxalitinib, again, in this frontline population.”
“I'm incredibly excited by the near-term opportunity to read out two Phase III trials that could establish new standards of care in two areas of high unmet need.”
Proxy statement
Start not stated–present
Last confirmed April 13, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Karyopharm Therapeutics Inc. (KPTI) | Chief Medical Officer and Head of Research | $567,736 | $2,016,134 |
| 2024 | Karyopharm Therapeutics Inc. (KPTI) | Chief Medical Officer and Head of Research | $567,736 | $1,124,444 |
| 2023 | Karyopharm Therapeutics Inc. (KPTI) | Chief Medical Officer and Head of Research | $545,900 | $1,227,789 |
